Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIb, Double Blind, Placebo-controlled Clinical Study Designed to Evaluate the Effect of CimetrA in Patients Diagnosed With COVID-19

NCT05037162 is registered in ClinicalTrials.gov with MGC Pharmaceuticals d.o.o as lead sponsor.

NCT NCT05037162
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05037162 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIb, Double Blind, Placebo-controlled Clinical Study Designed to Evaluate the Effect of CimetrA in Patients Diagnosed With COVID-19
Lead sponsor
MGC Pharmaceuticals d.o.o
Phase
Phase 2
Overall status
Completed
Start date
October 11, 2022
Completion date
March 1, 2023
Enrollment
240 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

corona virus infection, covid19